East Brunswick, NJNCT07601243Now EnrollingIRB Ready

Advanced Solid Tumors Clinical Trial in East Brunswick, NJ

Access cutting-edge advanced solid tumors treatment through this phase 1 clinical trial at a research site in East Brunswick. Study-provided care at no cost to qualified participants.

Sponsored by Gilead Sciences

Quick Self-Assessment

See if you qualify for this East Brunswick location

Preparing your pre-screening questions…

Expert Care in East Brunswick

Access advanced solid tumors specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced solid tumors treatment provided free

Apply for This East Brunswick Location

Check if you qualify for this advanced solid tumors clinical trial in East Brunswick, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to East Brunswick

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit East Brunswick site if eligible
  4. 4Begin participation

About This Advanced Solid Tumors Study in East Brunswick

The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in participants with advanced methylthioadenosine phosphorylase (MTAP)-deleted solid tumors. The primary objective of this study is to evaluate the safety and tolerability of GS-2426 in participants with MTAP-deleted advanced solid tumors and to determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) and the recommended phase II dose (RP2D).

Sponsor: Gilead Sciences

Who Can Participate

Inclusion Criteria

Participants 18 years of age or older (≥ 19 years old for participants in South Korea).
Histologically or cytologically confirmed advanced malignant solid tumors, who have progressed on, are intolerant to or are ineligible for standard therapy, or have no standard treatment options.
Participant tumors are methylthioadenosine phosphorylase (MTAP)-deficient.
Adequate organ function
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
All participants must provide a pretreatment tumor tissue sample. Key

Exclusion Criteria

Participants with plans to breastfeed during the study period or within 7 days following the last dose of study intervention.
Have not recovered (ie, returned to Grade 1 or baseline) from clinically significant adverse events (AEs) due to a previously administered agent or a previous intervention as assessed by the investigator.
Active second malignancy. Individuals with a history of malignancy who have been completely treated with no evidence of active cancer for 5 years prior to enrollment, or individuals with surgically cured tumors with low risk of recurrence may be enrolled.
Requirement for ongoing therapy with any prohibited medications .
Prior therapy with a protein arginine methyltransferase 5 (PRMT5) inhibitor or methionine adenosine transferase 2a (MAT2A) inhibitor.
Have serious infection requiring antibiotics within 14 days prior to the first dose.
Uncontrolled concurrent diseases Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in East Brunswick?

Yes, this clinical trial (NCT07601243) has an active research site in East Brunswick, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Solid Tumors Treatment Options in East Brunswick, NJ

If you're searching for advanced solid tumors treatment options in East Brunswick, NJ, this clinical trial (NCT07601243) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our East Brunswick research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced advanced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced solid tumors clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in East Brunswick, NJ

See all advanced solid tumors clinical trials recruiting in East Brunswick — not just this study.

Browse Advanced Solid Tumors Trials in East Brunswick →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAlzheimers Disease TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in East Brunswick?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · East Brunswick, NJ